Is Kymera Therapeutics Poised for a Breakthrough With KT-621?
Kymera Therapeutics advances KT-621 enrollment ahead of schedule, bringing pivotal atopic dermatitis data closer as it expands its protein degrader pipeline.
KYMR - Kymera Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$128.00
DETAILS
HIGH:
$155.00
LOW:
$97.00
MEDIAN:
$131.00
CONSENSUS:
$128.00
UPSIDE:
15.76%
Stock News
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm
NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Kymera Therapeutics, Inc. (NASDAQ: KYMR) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
SHAREHOLDER ALERT: Purcell and Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR) PR N
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
NEW YORK, July 16, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kymera Therapeutics, Inc. (NASDAQ: KYMR) on behalf of the company's shareholders. The investigation seeks to determine whether Kymera Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.
Kymera's CEO Sold $6 Million in Stock After a 170% Run
According to a Form 4, proceeds of approximately $6.0 million were realized from the exercise and immediate sale of 50,000 shares at $119.00 per share on July 7, 2026. The transaction reduced the insider's direct common stock holdings by 7%, leaving a residual direct position of 667,000 shares.
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026 and late 2027, respectively; Phase 3 trials in AD planned to initiate by mid-2027 WATERTOWN, Mass.
Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader
Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026 and late 2027, respectively; Phase 3 trials in AD planned to initiate by mid-2027 WATERTOWN, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Elizabeth Laws, Ph.D.
Kymera Therapeutics: Why It May Be Time To Jump On The Bandwagon (Upgrade)
Kymera Therapeutics (KYMR) is upgraded to Buy, driven by strong pipeline progress and a robust $1.5bn cash position. KT-621, an oral STAT6 degrader for atopic dermatitis, has accelerated Phase 2b timelines with topline data now expected by year-end 2026. KT-621's oral administration and promising early efficacy/safety data position KYMR to challenge injectable incumbents in a multi-billion dollar market.
Kymera: Building Toward A Defining 2H26 Moment
Kymera Therapeutics is rated Buy ahead of the 2H26 KT-621 Phase 2b readout, seen as a key inflection point. KT-621, a first-in-class oral STAT6 degrader, targets large, expanding markets in atopic dermatitis and other type 2 inflammatory diseases. Rapid trial enrollment, a strong balance sheet ($1.55B cash), and external validation position KYMR for potential high-value partnerships and lifecycle expansion.
KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.
Why Kymera Therapeutics Stock Popped This Week
It completed the enrollment phase of a Phase 2b study of its leading drug candidate. This medication will be trialed to gauge its efficacy in treating severe atopic dermatitis.
Kymera Jumps 17% on Early Enrollment Completion in Skin Disease Study
KYMR stock soars 17% as investor optimism was lifted following early enrollment completion in mid-stage AD study, moving KT-621 top-line data to year-end 2026.
Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?
Kymera Therapeutics (KYMR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program
Kymera Therapeutics Inc. (NASDAQ:KYMR) shares are trading higher by more than 21% on Thursday as the company has completed enrollment in its BROADEN2 Phase 2b trial for KT-621, a treatment for moderate to severe atopic dermatitis.
Biotech ETF Index Surges 10% After Rebalance
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
BROADEN2 enrollment completed nearly six months ahead of anticipated timelines KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 WATERTOWN, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced it has completed enrollment in the global BROADEN2 Phase 2b trial of KT-621, its first-in-class, oral STAT6 degrader, for the treatment of moderate to severe atopic dermatitis (AD).
Kymera Therapeutics Appoints Felix J. Baker, Ph.D.
Bruce Booth, DPhil, Co-Founder and Chairman, to remain an Independent Director WATERTOWN, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Felix J.
Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock?
Kymera Therapeutics (KYMR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting
Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and PK/PD results consistent with previously reported KT-621 clinical studies
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.
Price Targets
Kymera Therapeutics price target raised to $140 from $120 at Mizuho
$140.00
(was $114.12)
Joseph Catanzaro
·
Mizuho Securities
Kymera Therapeutics downgraded to Sector Perform from Outperform at RBC Capital
$115.00
(was $119.35)
Brian Abrahams
·
RBC Capital
Kymera Therapeutics price target raised to $136 from $116 at Truist
$136.00
(was $108.12)
Srikripa Devarakonda
·
Truist Financial
Kymera Therapeutics price target raised to $129 from $106 at Canaccord
$129.00
(was $116.46)
Edward Nash
·
Canaccord Genuity
Kymera Therapeutics (KYMR) PT Raised to $155 at B.Riley
$155.00
(was $116.46)
Kalpit Patel
·
B.Riley Financial
Kymera Therapeutics (KYMR) PT Raised to $97 at Brookline Capital Markets
$97.00
(was $73.95)
Leah Rush Cann
·
Loop Capital Markets
Kymera Therapeutics initiated with a Buy at Canaccord
$106.00
(was $82.71)
Edward Nash
·
Canaccord Genuity
Kymera Therapeutics price target lowered to $119 from $123 at Morgan Stanley
$119.00
(was $80.73)
Judah Frommer
·
Morgan Stanley
Kymera Therapeutics (KYMR) PT Lowered to $123 at Morgan Stanley
$123.00
(was $95.03)
Judah Frommer
·
Morgan Stanley
Kymera Therapeutics (KYMR) PT Raised to $108 at RBC Capital
$108.00
(was $91.87)
Brian Abrahams
·
RBC Capital
Kymera Therapeutics assumed with an Overweight at Barclays
$133.00
(was $72.15)
Eliana Merle
·
Barclays
Kymera Therapeutics price target raised to $103 from $70 at RBC Capital
$103.00
(was $85.62)
RBC Capital
Kymera Therapeutics price target raised to $110 from $65 at Stephens
$110.00
(was $89.89)
Sudan Loganathan
·
Stephens
Kymera Therapeutics price target raised to $120 from $81 at Mizuho
$120.00
(was $89.89)
Mizuho Securities
Kymera Therapeutics price target raised to $122 from $73 at Jefferies
$122.00
(was $86.82)
Jefferies
Kymera Therapeutics price target raised to $116 from $80 at Truist
$116.00
(was $86.27)
Srikripa Devarakonda
·
Truist Financial
Kymera Therapeutics price target raised to $134 from $84 at H.C. Wainwright
$134.00
(was $86.87)
Andrew Fein
·
H.C. Wainwright
Kymera Therapeutics price target raised to $120 from $67 at Oppenheimer
$120.00
(was $85.59)
Oppenheimer
Kymera Therapeutics price target raised to $127 from $73 at Morgan Stanley
$127.00
(was $87.21)
Morgan Stanley
Kymera Therapeutics price target raised to $125 from $98 at Piper Sandler
$125.00
(was $94.30)
Piper Sandler